Tolero Pharmaceuticals in the Daily Herald
April 29, 2018
This concept is based on the idea that drugs can be more effective once doctors know whether or not they will be right for specific patients. “It’s the right drug for the right patient for the right disease,” said Kelly Slone, president and CEO of BioUtah.
Tolero has already seen success testing this type of drug for treating acute myeloid leukemia. As Tolero Pharmaceuticals CEO David Bears said, “Now what we’re trying to do is develop a drug, and we say, ‘this drug isn’t for everybody, but we have a way to tell whether it’s for you.’ I want to see my discoveries move into something that can help people, that’s motivating to me, thinking I can help people with something I’ve discovered in our lab.”
Click here to read the full article
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
